drugset / Trial / NCT02714504
Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened with dermatologic examination. In the presence of any skin lesion in the extremities, direct exam and fungal culture will be performed. If these exams indicate the presence of Fusarium species, patients will receive anti-mold azole prophylaxis
Timeline
- Start
- 2008-08
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Posaconazole | Small molecule | 200 mg | — |
| Subject | Voriconazole | Small molecule | 200 mg | — |